|
Novel Breast Cancer Therapies: Antibody-Drug Conjugates
STATEMENT OF NEED
Breast cancer is the most common cancer diagnosed in women, with an estimated 15% of cases being human epidermal growth factor receptor 2 (HER2)"positive and 12% being triple-negative (ACS, 2019). Antibody-drug conjugates have revolutionized the treatment of HER2-positive, triple-negative, and, most recently, HER2-low unresectable or metastatic breast cancer. These drugs combine a tumor antigen"targeted monoclonal antibody with a cytotoxic payload to permit the s... |
|
|
Novel Breast Cancer Therapies: Immune Checkpoint Inhibitors
STATEMENT OF NEED
Breast cancer is the most common cancer diagnosed in women, and it is
estimated that 12% of cases are classified as triple-negative for estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 (HER2) (ACS, 2019). Immune checkpoint inhibition in combination with chemotherapy is a new strategy in breast cancer, with the first immunotherapy approval for patients with advanced triple-negative disease occurring in 2019. Immune checkpoint inhibit... |
|
|
Novel Breast Cancer Therapies: CDK4/6 Inhibitors
STATEMENT OF NEED
Breast cancer is the most common cancer diagnosed in women, with 287,850 new cases and 43,250 deaths predicted to occur in 2022 (ACS, 2022). Making up 73% of cases, hormone receptor (HR)"positive/human epidermal growth factor receptor 2 (HER2)"negative disease is the most common subtype of breast cancer (ACS, 2019). Cyclin-dependent kinase 4/6 (CDK4/6) inhibitors are a novel therapeutic option for patients with HR-positive, HER2-negative advanced breast cancer. T... |
|
|
Novel Breast Cancer Therapies: HER2 Tyrosine Kinase Inhibitors
STATEMENT OF NEED
Breast cancer is the most common cancer diagnosed in women, and it is estimated that 15% of cases are HER2-positive and may therefore benefit from human epidermal growth factor receptor 2 (HER2) inhibition (ACS, 2019). By blocking downstream oncogenic signaling in HER2-positive breast cancer cells, HER2 tyrosine kinase inhibitors improve outcomes for patients with HER2-positive breast cancer. These agents have advantages over monoclonal antibody HER2 inhibitors because the... |
|
|
Novel Breast Cancer Therapies: Monoclonal Antibodies
STATEMENT OF NEED
Breast cancer is the most common cancer diagnosed in women, and it is estimated that 15% of cases are human epidermal growth factor receptor 2 (HER2)"positive and may therefore benefit from HER2 inhibition (ACS, 2019). Monoclonal antibodies target HER2 function by preventing the formation or blocking the signaling of the oncogene HER2. The resulting loss of signaling downregulates oncogenic signaling in the cancer cell, resulting in improved clinical outcomes for pati... |
|
|
Novel Breast Cancer Therapies: PARP Inhibitors
STATEMENT OF NEED
Breast cancer is the most commonly diagnosed cancer in women. A BRCA1 or BRCA2 mutation is found in approximately 5% of patients with breast cancer and is detected in 30% of patients who have a family history of breast or ovarian cancer (ACS, 2019). In patients with human epidermal growth factor receptor 2 (HER2)"negative breast cancer with deleterious or suspected deleterious germline BRCA mutations, inhibition of poly"(ADP-ribose) polymerase (PARP) is highly ef... |
|
|
Novel Breast Cancer Therapies: PI3K Inhibitors
STATEMENT OF NEED
Breast cancer is the most diagnosed cancer in women, with hormone receptor (HR)"positive/human epidermal growth factor receptor 2 (HER2)"negative breast cancer being the most common subtype, making up 73% of cases (ACS, 2019). In breast cancer, phosphatidylinositol-3-kinase (PI3K) overactivation is often associated with an activating mutation in the catalytic alpha subunit of PI3K (PIK3CA). These activating mutations occur in more than one third of breast cancers... |
|
|
Evolving Treatment Concepts and New Data in Advanced Prostate Cancer
STATEMENT OF NEED
Prostate cancer is the most common tumor type affecting men in the United States. It is estimated that 268,490 new cases were diagnosed and that 34,500 people died of prostate cancer in 2022 (Siegel et al, 2022). Prostate cancer alone accounts for 27% of all cancer diagnoses in men (ACS, 2022). To optimize outcomes for patients with prostate cancer, it is critical for health care providers to be familiar with the most recent evidence on therapy selection, biomarker testing... |
|
|
Cracking the Code for Improved Patient Outcomes in Advanced Renal Cell Carcinoma
STATEMENT OF NEED
Renal cell carcinoma (RCC) comprises 2.4% of malignancies in adults worldwide (Makino et al, 2022). It is estimated that 79,000 new cases of kidney cancer were diagnosed in the US in 2022 (Siegel et al, 2022). RCC is characterized by a lack of early warning signs, diverse clinical manifestations, and resistance to radiation and chemotherapy. Several new therapies have been approved for RCC in recent years; therefore, it is important for the cancer care team to update their... |
|
|
Virtual Tumor Board: Building Comprehensive Care Plans in Esophagogastric Cancers
STATEMENT OF NEED
Esophagogastric cancers include tumors of the esophagus, esophageal junction, and stomach. Esophageal cancers are the twentieth most commonly diagnosed cancer in the United States, but the eleventh leading cause of cancer death, with an estimated 21,560 cases diagnosed annually and 16,120 deaths estimated in 2023 (NCCN, 2023; Siegel et al, 2023). Given the poor prognosis of esophagogastric cancers and the complexity of personalized care planning, interdisciplinary teamwork... |
|
|
Leveraging BCMA-Directed Therapies for Improved Patient Outcomes in Relapsed/Refractory Multiple Myeloma
STATEMENT OF NEED
Multiple myeloma is a disease that remains incurable for most patients, many of whom become refractory to the majority of available treatments (Kumar et al, 2022). It is estimated that 35,730 new cases of multiple myeloma are diagnosed in the United States annually, and 12,590 people die of the disease (Siegel et al, 2023). Agents targeting B-cell maturation antigen (BCMA), including antibody-drug conjugates (ADCs), chimeric antigen receptor (CAR) T-cell therapies, and bis... |
|
|
Hitting the Target in HER2-Positive Metastatic Colorectal Cancer
STATEMENT OF NEED
An estimated 153,020 new cases of colorectal cancer (CRC) are diagnosed annually, and 52,550 people die of the disease (Siegel et al, 2023). Approximately 22% of patients present with metastatic disease, which is associated with a dismal 5-year survival rate of 15% (SEER, 2022). Targeting biomarkers is a key strategy for expanding therapeutic options and improving outcomes in metastatic CRC. Human epidermal growth factor receptor 2 (HER2) amplification status and treatment... |
|
|
Expert Guidance on Current Standards and New Directions in Newly Diagnosed Multiple Myeloma
STATEMENT OF NEED
An estimated 35,730 new cases of multiple myeloma are diagnosed in the United States annually, and 12,590 people die of the disease (Siegel et al, 2023). Characterized by clonal proliferation of malignant plasma cells in the bone marrow, multiple myeloma is associated with anemia, renal insufficiency, bone destruction, and hypercalcemia, all of which significantly impact patients’ quality of life. The development of novel therapies and combinations in recent years, inclu... |
|
|
Leveraging the Growing Arsenal of Adjuvant Therapies for Early-Stage NSCLC
In this activity, Dr. Helena A. Yu, Associate Attending Physician at Memorial Sloan Kettering Cancer Center, will provide insights into strategies for leveraging the growing arsenal of adjuvant therapies for early-stage non"small cell lung cancer (NSCLC), including treatment selection and adverse event management. Start the activity now!
STATEMENT OF NEED
Lung cancer is the second most commonly diagnosed cancer and the leading cause of death for men and women worldwide. In the Unite... |
|
|
Pathology and Oncology Expert Perspectives in the Management of Triple-Negative Breast Cancer: Case Explorations and Answers to FAQs
STATEMENT OF NEED
Triple-negative breast cancer (TNBC) is an aggressive disease that accounts for approximately 10% to 15% of breast cancer diagnoses and is characterized by the absence of estrogen receptors, progesterone receptors, and human epidermal growth factor receptor 2 (HER2). TNBC is more common in Black women and in women under the age of 40 (ACS, 2023). Compared with other subtypes of invasive breast cancer, TNBC has high rates of metastasis and a poor prognosis. Due to the lack ... |
|
|
Virtual Tumor Board: Multidisciplinary Management of Advanced Soft Tissue Sarcoma
STATEMENT OF NEED
Sarcomas, which represent 1% to 2% of adult cancers, are a rare, heterogeneous group of neoplasms originating in the connective tissue. Soft tissue sarcomas, which begin in the muscle, tendons, fat, lymph, blood vessels, and nerves, encompass more than 80 histological subtypes. Approximately 25% of patients develop metastatic disease after curative-intent surgery, and for these patients, treatment options are limited and prognosis is very poor. In recent decades, the ident... |
|
|
Managing Immune Related Adverse Events to Ensure Optimal Cancer Immunotherapy Outcomes: The Nurse’s View
STATEMENT OF NEED
Immune checkpoint inhibitors, which alter immune regulatory pathways and promote cell-mediated destruction of tumor cells, have revolutionized the treatment of cancer in recent years, with numerous therapeutic agents approved and several targets under investigation (Chennamadhavuni et al, 2022). However, up to 90% of patients receiving immune checkpoint inhibitors experience immune-related adverse events, which can affect a wide variety of organ systems and can occur at any ... |
|
|
Recurrent and Metastatic HNSCC: New Insights and Real-World Evidence for Improved Patient Outcomes
STATEMENT OF NEED
Head and neck cancers represent a heterogeneous group of tumors that originate in the lip/oral cavity, hypopharynx, oropharynx, nasopharynx, and larynx. An estimated 66,470 new cases are diagnosed in the United States annually, and 15,050 people die of the disease (Siegel et al, 2022). Approximately 90% of cases are classified as head and neck squamous cell carcinoma (HNSCC). Treatment of HNSCC is complicated by numerous factors, including differing therapeutic strategies ... |
|
|
Best Practices in Nursing Management of Chemotherapy-Induced Peripheral Neuropathy
STATEMENT OF NEED
Chemotherapy-induced peripheral neuropathy (CIPN) is a complication of cancer treatment that may impair quality of life and lead to dose reductions or discontinuation of treatment. In one study, among 105 patients receiving paclitaxel for breast cancer, 36.2% needed dose reductions due to CIPN (Timmins et al, 2021). Whereas in some patients the symptoms improve with time, in others, there is progression with permanent nerve damage (Zajączkowska et al, 2019). At present, the... |
|
|
Raising the Bar for Patient Outcomes With Immunotherapy in Early-Stage Resectable NSCLC
Target Audience
The target audience for this educational initiative is oncologists, oncology NPs, PAs, and nurses, pulmonologists, pulmonology NPs and PAs, pathologists, and pharmacists.
Program Overview
Are you up to date on the role of immunotherapy in the setting of non-small cell lung cancer (NSCLC)? In this educational activity, experts Heather Wakelee, MD, and Meghan Ramsey, MD, explore how to select patients with early-stage resectable NSCLC who may derive benefit from immunotherap... |
|
|
Applying the Latest Clinical Data in Multiple Myeloma Patient Care in the Community Setting
In recent years, there have been significant advances in multiple myeloma (MM) management, including approvals of new drugs and treatment combinations. For some patients, however, the benefits of these advances remain elusive: disparities in MM care among Black patients, who are more likely to be treated in the community setting, persist across the spectrum of MM care.
Though evidence-based MM treatment guidelines and consensus statements are available, ongoing studies continue to provide i... |
|
|
Is Colchicine the 2020 Comeback Kid?
Colchicine has been used in medicine for > 2000 years and current established uses include treatment of gout, Familial Mediterranean Fever, and pericarditis, although it has been studied in a wide range of conditions including atrial fibrillation, cancer, and more recently prevention of ischemic events in patients with coronary heart disease. Despite lifestyle changes and significant advances in medicine and interventional cardiology, patients with coronary heart disease remain at high risk fo... |
|
|
Evolving Treatment Paradigms in HR-Positive, HER2-Negative Breast Cancer: Integrating the Latest Evidence Into Clinical Practice
Target Audience
This activity is designed specifically for oncologists, advanced practice providers, and other members of the healthcare team who serve patients from rural and underserved communities.
Program Overview
Advances in therapy for patients with hormone receptor"positive (HR+)/human epidermal growth factor receptor 2"negative (HER2-) breast cancer have the potential to reduce disease recurrence and risk of mortality. However, the complex and evolving treatment landscap... |
|
|
Mitigating Disparities in Prostate Cancer Care: Strategies to Promote Equitable Care Across the Continuum
TARGET AUDIENCE
This activity is designed specifically for oncologists, advanced practice providers, and other members of the healthcare team who serve patients from rural and underserved communities.
PROGRAM OVERVIEW
Prostate cancer is among the most common cancers in the United States. In rural and underserved areas of the country, patients with prostate cancer often have poor outcomes due to limited access to care, lack of subspecialists, and long travel distances to treatment centers. I... |
|
|
Integrating the Latest Evidence on Immune Checkpoint Inhibitors Into the Management of Advanced Non-Small Cell Lung Cancer
Target Audience
This activity is designed specifically for oncologists, advanced practice providers, and other members of the healthcare team who serve patients from rural and underserved communities.
Program Overview
Rural counties in the US face a higher incidence of lung cancer than urban areas and also have higher rates of cancer-related mortality and other negative treatment outcomes. These statistics underscore the need for increased education among oncology clinicians in order to i... |
|
|
Integrating the Latest Evidence on Immune Checkpoint Inhibitors Into the Management of Advanced Non-Small Cell Lung Cancer
Target Audience
This activity is designed specifically for oncologists, advanced practice providers, and other members of the healthcare team who serve patients from rural and underserved communities.
Program Overview
Rural counties in the US face a higher incidence of lung cancer than urban areas and also have higher rates of cancer-related mortality and other negative treatment outcomes. These statistics underscore the need for increased education among oncology clinicians in order to i... |
|
|
Updates in the Diagnosis and Management of Chronic Lymphocytic Leukemia: Strategies for Addressing Disparities in Patient Care and Outcomes
Target Audience
This activity is designed specifically for oncologists, advanced practice providers, and other members of the healthcare team who serve patients from rural and underserved communities.
Program Overview
Advances in chronic lymphocytic leukemia (CLL) testing and therapy have redefined the standard of care in recent years, prompting updates to current guideline recommendations. At the same time, findings from ongoing clinical trials continue to inform treatment options and de... |
|
|
Transfusion-Related Iron Overload"Evidence-Based Approaches to Improve Chelation Outcomes
Target Audience
This educational activity is directed toward hematologists. Pediatricians, nurses, nurse practitioners, physician assistants, and other clinicians involved in the management of patients with iron overload are also invited to attend.
Program Overview
Patients who require ongoing red blood cell transfusions, such as individuals with transfusion-dependent thalassemia or sickle cell disease, may develop iron overload. Severe or long-term iron overload can result in a higher ri... |
|
|
Nursing Management of Cancer Treatment-Induced Cardiotoxicity
Studies have shown that certain cancer therapies adversely affect the heart and lead to various types of injuries, which often result in death. This activity reviews recent advances in the management of cancer teatment-induced cardiotoxicity.
STATEMENT OF NEED
Several studies reveal that certain cancer therapies adversely affect the heart and lead to various types of injuries, which often result in death. Adverse cardiac effects may occur immediately after cessation of therapy or, in som... |
|
|
Obesity Forum FAQs: A Podcast Series
Obesity is an increasingly prevalent, chronic condition associated with substantial risks of morbidity and mortality. It is also a risk factor for some of the leading causes of preventable death, including cardiovascular disease, stroke, type 2 diabetes mellitus, sleep apnea, gallbladder disease, osteoarthritis, and certain types of cancer. With prevalence continuing to escalate, it is predicted that 1 in 2 Americans will have obesity by 2030. The 10th Annual Obesity Forum was a 2-part series ... |
|
|
Obesity Forum®: Getting Engaged in Obesity Care
Obesity is an increasingly prevalent chronic condition associated with substantial risks of morbidity and mortality. It is also a risk factor for some of the leading causes of preventable death, including cardiovascular disease, stroke, type 2 diabetes mellitus, sleep apnea, gallbladder disease, osteoarthritis, and certain types of cancer. With prevalence continuing to escalate, it is predicted that 1 in 2 Americans will have obesity by 2030. Among the groups most at risk for severe obesity ar... |
|
|
Obesity Forum®: Individualizing Obesity Care and Challenging Cases
Obesity is an increasingly prevalent chronic condition associated with substantial risks of morbidity and mortality. It is also a risk factor for some of the leading causes of preventable death, including cardiovascular disease, stroke, type 2 diabetes mellitus, sleep apnea, gallbladder disease, osteoarthritis, and certain types of cancer. With prevalence continuing to escalate, it is predicted that 1 in 2 Americans will have obesity by 2030. Among the groups at risk for obesity are youths age... |
|
|
Evolving Paradigms in the Use of Checkpoint Inhibitors for the Management of Patients With Non-Small Cell Lung Cancer
Non-small cell lung cancer (NSCLC) accounts for approximately 85% of all lung cancer cases with most patients having advanced disease at the time of diagnosis. Recent updates to guidelines have further defined recommendations for screening, diagnosis, and biomarker testing for the early management of NSCLC. However, the COVID-19 pandemic has complicated the diagnosis and management of NSCLC, potentially impacting clinical outcomes in these patients. Treatment paradigms also continue to rapidly... |
|
|
Metastatic Colorectal Cancer: Targeting Key Clinical Issues for Oncology Nurses
Target Audience
This activity is designed to meet the educational needs of oncology nurses, nurse practitioners and nurse navigators engaged in the care of patients with metastatic colorectal cancer.
Program Overview
New targeted therapies for metastatic colorectal cancer have increased the need for awareness, education, and training for oncology nursing professionals to better prepare them to confidently manage and educate patients.
Learning Objectives
Upon completion of this activit... |
|
|
Metastatic Colorectal Cancer: Targeting Key Clinical Issues for Oncology Nurses
New targeted therapies for metastatic colorectal cancer have increased the need for awareness, education, and training for oncology nursing professionals to better prepare them to confidently manage and educate patients.
Upon completion of this activity, participants should be better able to:
Assess appropriate treatment options for a patient with mCRC who has failed first- and second-line treatment regimens
Outline toxicities and management considerations with specific treatment regi... |
|
|
Putting the CAR(T) Before the Horse: Practicalities of T Cell-Activating Therapies in Multiple Myeloma
ACTIVITY DESCRIPTION
Patients with multiple myeloma that is refractory to multiple classes of therapeutics can be particularly difficult to treat. Fortunately, the treatment landscape is expanding, and a range of new therapies for patients with multiply relapsed or refractory multiple myeloma (RRMM) is rapidly emerging. In particular, chimeric antigen receptor (CAR) T-cell therapy is a powerful new immunotherapy that has revolutionized cancer treatment and has been approved for patients with ... |
|
|
On the Horizon: HER3-Targeted Antibody-Drug Conjugates for Advanced Solid Tumors An Infographic-Enhanced Journal Club Activity Rationale and Mechanism of Action of HER3-Targeted ADCs for Advanced NSCL
Target Audience
This activity has been designed for oncology clinicians and others who may also have an interest in this topic, specifically those focused on lung and/or breast cancer.
Program Overview
Although treatments for advanced non-small cell lung cancer (NSCLC) and breast cancer are rapidly advancing, these diseases remain incurable. Antibody-drug conjugates (ADCs) offer a novel approach to targeting HER3 as a method of delivering a cytotoxic payload that eliminates tumor cells. T... |
|
|
Identifying Patients at High Risk of COVID-19 Complications: Considerations for Community Care to Reduce Morbidity, Mortality, and Hospitalization Risk
Target Audience
This activity is designed to meet the educational needs of primary care physicians, internists, pharmacists, nurses, nurse practitioners, physician assistants, and other members of the multidisciplinary team to ensure optimal patient outcomes in outpatient management of COVID-19 infection and potential complications of disease in at-risk populations.
Program Overview
This program uses a game-based approach to explore the current understanding of COVID risk assessment, diag... |
|
|
A New Path Forward: The Therapeutic Potential of Next Generation BTK Inhibitors in CLL/SLL
Emerging BTK inhibitors are positioned to change the landscape and impact your chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) treatment plans. Are you ready to incorporate these emerging therapies into your treatment plans? Dr. Sameer Parikh discusses these emerging BTK inhibitors for CLL/SLL, how they differ from current approaches, and future opportunities to introduce these therapies into your clinical decisions. Hear a patient case and the question and answer portion f... |
|
|
Early Detection of Women’s Cancers: A Prominent Role for Primary Care and OB/GYNs
Target Audience
The educational design of this activity addresses the needs of primary care physicians (PCPs), OB/GYNs, and NPs/PAs working in primary care or women’s care centers involved in the treatment of patients at higher risk for women’s cancers.
Program Overview
Multi‐cancer early detection panels (MCEDs) have the potential to improve cancer outcomes by enhancing timely screening and detection of multiple cancers at once, including high‐incidence cancers without current gu... |
|
|
Updates in General Internal Medicine for Specialists 2024 - LIVE STREAMING or IN PERSON
Advances, Updates, Guidelines, and Best Practices in General Internal Medicine"Expressly for Specialists
Updates in General Internal Medicine for Specialists will be held January 29"February 2, 2024. You can attend online as the course is live streamed, or in person in Boston, MA. All sessions will be recorded and made available to all participants to view online, at your convenience.
Overview
In this unique program, Harvard Medical School's leading clinical faculty, rep... |
|
|
Ace the Case: Multiple Myeloma Presentation in the Community Setting
Effective treatment of multiple myeloma (MM) requires significant clinical coordination, as MM treatment plans are highly individualized. Treatment is influenced by many factors, including patient demographics, biomarkers, level of disease progression, response to previous treatments, individual treatment goals, and the preferred treatment paradigms of individual practitioners.
This educational program is designed to meet the educational needs of the members of the care team (oncologists, h... |
|
|
Ace the Case: Treating First Multiple Myeloma Relapse in the Community Setting
Effective treatment of multiple myeloma (MM) requires significant clinical coordination, as MM treatment plans are highly individualized. Treatment is influenced by many factors, including patient demographics, biomarkers, level of disease progression, response to previous treatments, individual treatment goals, and the preferred treatment paradigms of individual practitioners.
This educational program is designed to meet the educational needs of the members of the care team (oncologists, h... |
|
|
Ace the Case: R/R MM After 4 Lines of Therapy: What are the options?
Effective treatment of multiple myeloma (MM) requires significant clinical coordination, as MM treatment plans are highly individualized. Treatment is influenced by many factors, including patient demographics, biomarkers, level of disease progression, response to previous treatments, individual treatment goals, and the preferred treatment paradigms of individual practitioners.
This educational program is designed to meet the educational needs of the members of the care team (oncologists, h... |
|
|
Expert Insight into Emerging Treatments for EGFR TKI-Resistant NSCLC and HER2-Positive NSCLC
Target Audience
Medical oncologists, thoracic oncologists, pathologists, oncology nurse practitioners, oncology physician assistants, and other HCPs managing patients with NSCLC
Program Overview
Despite substantial advances in the management of non-small cell lung cancer (NSCLC) during the past decade, advanced NSCLC continues to have persistently low 5-year survival rates and imposes a significant burden on patients. Improved molecular-testing practices and integration of new data on tar... |
|
|
Ace the Case: Newly Diagnosed AML: Can Molecular Markers Direct Treatment?
Knowledge of the key management issues for patients with AML is critical. Patients receiving both standard chemotherapy and newer agents need to be monitored for, and educated about, the risk of infection, bleeding and potential adverse events associated with treatment. Early identification and intervention are critical to reduce the potential for serious adverse events and complications. |
|
|
Ace the Case: Older Adult with Therapy-Related AML
Knowledge of the key management issues for patients with AML is critical Patients receiving both standard chemotherapy and newer agents need to be monitored for, and educated about, the risk of infection, bleeding and potential adverse events associated with treatment. Early identification and intervention are critical to reduce the potential for serious adverse events and complications. |
|
|
Ace the Case: Supporting Older Adults with AML
Knowledge of the key management issues for patients with AML is critical. Patients receiving both standard chemotherapy and newer agents need to be monitored for, and educated about, the risk of infection, bleeding and potential adverse events associated with treatment. Early identification and intervention are critical to reduce the potential for serious adverse events and complications. |
|
|
An Innovative View: Evaluating Combination Checkpoint Inhibition Strategies in Advanced Melanoma: Considerations with Anti-LAG3 Antibodies
Target Audience
This activity is designed to meet the educational needs of oncologists, dermatologists, nurse practitioners, oncology pharmacists, and physician assistants to ensure confidence in the management of advanced melanoma.
Program Overview
This online program is designed to help oncologists, dermatologists, nurse practitioners, oncology pharmacists, and physician's assistants to ensure confidence in the management of advanced melanoma. We aim to evaluate the pathophysiology... |
|
|
Addressing Health Care Disparities and Improving Patient Outcomes in Prostate Cancer: Expert Perspectives on Optimizing ADT
Prostate cancer is the leading cause of cancer and the second leading cause of cancer death in men in the United States. Medical androgen deprivation therapy (ADT) is the standard of care for advanced prostate cancer but may be associated with a broad range of adverse effects. Increased risk of cardiovascular (CV) events is among the most serious, as CV disease is the most common non-cancer cause of death in prostate cancer patients. Although evidence-based guidelines on ADT selection and CV r... |
|